SHW Stock Analysis: Sherwin-Williams | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 86.108m USD | 12M Return: -4.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 889M
EPS Trend: 95.0%
Qual. Beats: 0
Rev. Trend: 76.8%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sherwin-Williams Co. (SHW) is a global manufacturer and distributor of paints, coatings, and related products serving professional, industrial, commercial, and retail customers. The company operates through three business segments - Paint Stores Group, Consumer Brands Group, and Performance Coatings Group - which collectively cover architectural coatings, industrial and protective finishes, automotive refinish products, wood finishes, and specialty resins sold via company-owned retail stores, home centers, dealers, and third-party distributors. Headquartered in Cleveland, Ohio, and founded in 1866, SHW has expanded its operations across North America, South America, the Caribbean, Europe, Asia, and Australia, and has been publicly traded on the NYSE since 1985.
The company is classified within the GICS Materials sector, under the Specialty Chemicals sub-industry, reflecting that coatings are formulated chemical products rather than basic commodities. A defining feature of Sherwin-Williams business model is its vertical integration: it develops and manufactures coatings in-house and sells them directly to end users through its proprietary Sherwin-Williams-branded stores, a structure that distinguishes it from competitors who rely more heavily on independent distribution channels.
- Housing starts and DIY demand boost Paint Stores Group sales
- Raw material costs squeeze margins despite pricing actions
- Performance Coatings cyclical exposure weighs on industrial volume growth
| Net Income: 2.60b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.18 > 1.0 |
| NWC/Revenue: -4.32% < 20% (prev -7.97%; Δ 3.65% < -1%) |
| CFO/TA 0.14 > 3% & CFO 3.65b > Net Income 2.60b |
| Net Debt (15.7b) to EBITDA (4.47b): 3.50 < 3 |
| Current Ratio: 0.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (248.1m) vs 12m ago -1.74% < -2% |
| Gross Margin: 49.12% > 18% (prev 48.72%; Δ 0.40% > 0.5%) |
| Asset Turnover: 93.84% > 50% (prev 93.51%; Δ 0.33% > 0%) |
| Interest Coverage Ratio: 7.83 > 6 (EBIT TTM 3.86b / Interest Expense TTM 492.8m) |
| A: -0.04 (Total Current Assets 6.50b - Total Current Liabilities 7.53b) / Total Assets 26.4b |
| B: 0.05 (Retained Earnings 1.37b / Total Assets 26.4b) |
| C: 0.15 (EBIT TTM 3.86b / Avg Total Assets 25.5b) |
| D: 0.20 (Book Value of Equity 4.43b / Total Liabilities 21.9b) |
| Altman-Z'' = 1.14 = BB |
| DSRI: 1.09 (Receivables 3.19b/2.81b, Revenue 23.9b/23.0b) |
| GMI: 0.99 (GM 48.72% / 49.12%) |
| AQI: 0.98 (AQ_t 0.52 / AQ_t-1 0.53) |
| SGI: 1.04 (Revenue 23.9b / 23.0b) |
| TATA: -0.04 (NI 2.60b - CFO 3.65b) / TA 26.4b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of July 10, 2026, the stock is trading at USD 332.03 with a total of 932,992 shares traded. Over the past week, the price has changed by -4.05%, over one month by +6.92%, over three months by -0.85% and over the past year by -4.67%.
Current recommended Stop Loss: 319.40 (which is 3.8% or 1.3 ATR below the current price).
Sherwin-Williams has received a consensus analysts rating of 3.79. Therefore, it is recommended to hold SHW.
- StrongBuy: 10
- Buy: 5
- Hold: 11
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 374.2 | 12.7% |
P/E Trailing = 33.5702
P/E Forward = 29.9401
P/S = 3.632
P/B = 19.6191
P/EG = 2.7236
Revenue TTM = 23.9b USD
EBIT TTM = 3.86b USD
EBITDA TTM = 4.47b USD
Long Term Debt = 9.32b USD (from longTermDebt, last quarter)
Short Term Debt = 2.86b USD (from shortTermDebt, last quarter)
Debt = 15.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.09b
Net Debt = 15.7b USD (calculated: Debt 15.9b - CCE 216.9m)
Enterprise Value = 102b USD (86.1b + Debt 15.9b - CCE 216.9m)
Interest Coverage Ratio = 7.83 (Ebit TTM 3.86b / Interest Expense TTM 492.8m)
EV/FCF = 35.03x (Enterprise Value 102b / FCF TTM 2.91b)
FCF Yield = 2.85% (FCF TTM 2.91b / Enterprise Value 102b)
FCF Margin = 12.14% (FCF TTM 2.91b / Revenue TTM 23.9b)
Net Margin = 10.86% (Net Income TTM 2.60b / Revenue TTM 23.9b)
Gross Margin = 49.12% ((Revenue TTM 23.9b - Cost of Revenue TTM 12.2b) / Revenue TTM)
Gross Margin QoQ = 49.07% (prev 48.84%)
Tobins Q-Ratio = 3.86 (Enterprise Value 102b / Total Assets 26.4b)
Interest Expense / Debt = 3.10% (Interest Expense 492.8m / Debt 15.9b)
Taxrate = 22.75% (765.7m / 3.37b)
NOPAT = 2.98b (EBIT 3.86b * (1 - 22.75%))
Current Ratio = 0.86 (Total Current Assets 6.50b / Total Current Liabilities 7.53b)
Debt / Equity = 3.58 (Debt 15.9b / totalStockholderEquity, last quarter 4.43b)
Debt / EBITDA = 3.50 (Net Debt 15.7b / EBITDA 4.47b)
Debt / FCF = 5.39 (Net Debt 15.7b / FCF TTM 2.91b)
Total Stockholder Equity = 4.46b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.19% (Net Income 2.60b / Total Assets 26.4b)
RoE = 58.23% (Net Income TTM 2.60b / Total Stockholder Equity 4.46b)
RoCE = 27.98% (EBIT 3.86b / Capital Employed (Equity 4.46b + L.T.Debt 9.32b))
RoIC = 13.87% (NOPAT 2.98b / Invested Capital 21.5b)
WACC = 7.20% (E(86.1b)/V(102b) * Re(8.09%) + D(15.9b)/V(102b) * Rd(3.10%) * (1-Tc(0.23)))
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -1.54%
[DCF] Terminal Value 77.97% ; FCFF base≈2.61b ; Y1≈3.00b ; Y5≈4.41b
[DCF] Fair Price = 205.5 (EV 66.3b - Net Debt 15.7b = Equity 50.7b / Shares 246.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.01 | EPS CAGR: 4.76% | SUE: 0.38 | # QB: 0
Revenue Correlation: 76.85 | Revenue CAGR: 1.07% | SUE: 1.14 | # QB: 1
EPS current Quarter (2026-06-30): EPS=3.52 | Chg30d=+0.45% | Revisions=+0% | Analysts=19
EPS next Quarter (2026-09-30): EPS=3.58 | Chg30d=-0.26% | Revisions=+0% | Analysts=19
EPS current Year (2026-12-31): EPS=11.73 | Chg30d=-0.08% | Revisions=-30% | GrowthEPS=+2.7% | GrowthRev=+4.9%
EPS next Year (2027-12-31): EPS=13.25 | Chg30d=-0.29% | Revisions=+22% | GrowthEPS=+12.9% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: -4% (up=10, down=11)